Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 159   

Articles published

NVS 70.65 +0.22 (0.31%)
price chart
Analyst Review Alert on Price Target: Novartis AG (ADR) (NYSE:NVS)
Novartis AG (ADR) (NYSE:NVS) plunged -1.50% during previous trade, a total of 5.42M shares exchanged hands compared with its average trading volume of 3.39M shares whereas its relative volume is 1.96.
European Influenza Market May Reach Close To $650 Million by 2021, Who ...  Stock Market Daily (blog)
Can Novartis AG (ADR) (NVS) Survive with Alcon Crisis?
Novartis AG (ADR) (NYSE:NVS) is considering the sale of its eye care division, Alcon, due to its revenue decline in the last two years.
Novartis AG (NVS) Seeks M&A as It Mulls Possible Alcon Sale
Novartis AG (ADR) (NYSE:NVS) is planning to enter into mergers and acquisitions as it continues to weigh options for the long-struggling eye-care business Alcon.
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Will Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges?
Novartis AG (ADR) (NYSE:NVS) is hit by bad news of involvement of its six senior officials under the charges of corruption.
Novartis AG (NYSE:NVS) To Spend $100 Million On Expansion Of French mAb Plant  Market Exclusive
Will Novartis AG (ADR) (NVS) Cosentyx Lead Psoriasis Therapeutic Market?
Keeping in view fierce competition in the future as well as the patent cliff side effects, Novartis AG (ADR) (NYSE:NVS) is working on its blockbuster molecule Cosentyx to be the market leader in the management and treatment of psoriasis.
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration
Novartis AG (ADR) (NYSE:NVS) is currently going through an era of patent expiration as patents of its blockbuster drug Gleevec has expired, leading to a revenue dip.
Here's What's Important With The Novartis AG (ADR) (NVS) MS Data  Insider Monkey (blog)
Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words  Market Exclusive
Ford Motor Company (NYSE:F) & Novartis AG (ADR) (NYSE:NVS) Stocks in the Spotlight
On Thursday, Shares of Ford Motor Company (NYSE:F) lost -0.63% to $12.59. The share price is trading in a range of $12.35 - 12.68.
Amgen, Inc. (AMGN) and Novartis AG (ADR) (NVS) Erenumab: New Hope for Migraine ...
Amgen, Inc. (NASDAQ:AMGN) has announced that erenumab clinical results for the management and treatment of chronic migraine headaches have met the primary endpoints.
Novartis Reports Positive Phase II Data on Migraine Drug  Nasdaq